Clinical trials
Transplant clinical trials
Below are recruiting transplant clinical trials, each written for real people, not researchers. We’re tracking 1,499 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06425666Recruiting
Cataract surgery with triple-DMEK for Fuchs dystrophy
This trial tests a combined surgery that treats both cataract and Fuchs endothelial corneal dystrophy at the same time. It compares the standard cataract surgery to one that also replaces the damaged cornea layer, aiming to improve vision with fewer steps.
Aarhus N, Central JutlandAges 18 years+ - NCT06427330RecruitingPhase 2
Low-Dose Inotuzumab After Transplant to Prevent Leukemia Relapse
This trial tests whether a low dose of a targeted drug called inotuzumab ozogamicin, given after a stem cell transplant, can help prevent acute lymphoblastic leukemia from coming back. It is for people who have already had a transplant and are at high risk for relapse.
TianjinAges 18 years+ - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06458244Recruiting
Stem cell transplant for high-risk CBF-AML
This trial tests a stem cell transplant (using donor cells) for people with a high-risk form of acute myeloid leukemia called CBF-AML. The goal is to see if this transplant can help patients who have a higher chance of the leukemia coming back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06461208RecruitingPhase 3
Fecal transplant for people with cirrhosis
This trial tests whether transplanting healthy gut bacteria (from donor stool) can improve outcomes in people with cirrhosis. If you have mild to moderate cirrhosis, you may be able to join.
BasildonAges 18 years+ - NCT06463717Recruiting
Stem cell transplant timing for multiple myeloma with no cancer cells left
This trial looks at people with newly diagnosed multiple myeloma who have no detectable cancer cells after initial treatment. It aims to see if these patients can do well without a stem cell transplant or with a delayed one, reducing unnecessary side effects.
Hangzhou, ZhejiangAges 18–70 - NCT06464016Recruiting
Infections in Kids With Berlin Heart Pumps
This study looks at infections in children who used a Berlin Heart mechanical heart pump. It aims to find better ways to prevent and treat these infections.
LyonAges 1 day–18 years - NCT06490627RecruitingPhase 2
thalidomide for transfusion-dependent beta thalassemia
This trial tests different doses of thalidomide to see if it can reduce or eliminate the need for blood transfusions in people with beta thalassemia major or intermedia.
Karachi, SindhAges 8–35 - NCT06490744Recruiting
Lung function after COVID-19 in lung transplant patients
This study looks at how lung function changed over time in lung transplant patients who had a moderate to severe COVID-19 infection. It may help doctors understand how to better care for transplant patients after a serious COVID-19 illness.
StrasbourgAges 18 years+ - NCT06494033Recruiting
CMV prevention after lung transplant based on immune status
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
Miami, FloridaAges 18–75 - NCT06498310Recruiting
Fungal infections in heart transplant patients (2008–2022)
This study looks back at heart transplant patients who had a serious fungal infection from thread-like fungi (like mold) between 2008 and 2022. It aims to learn more about these infections to improve care for future patients.
StrasbourgAges 18 years+ - NCT06498973RecruitingPhase 1
Maintenance therapy after stem cell transplant for CD123-positive AML/MDS
This trial tests a combination of two drugs, tagraxofusp and azacitidine, given as maintenance therapy after a stem cell transplant. The goal is to prevent the leukemia or MDS from coming back in patients whose cancer cells carry a specific marker called CD123.
Duarte, CaliforniaAges 18–75 - NCT06505369RecruitingPhase 2
Immune therapy for newly diagnosed multiple myeloma before stem cell transplant
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
CopenhagenAges 18–70 - NCT06509945Recruiting
Donor stem cell transplant for high-risk T-cell lymphoma
This trial tests giving a donor stem cell transplant (called allo-PBSCT) as the first treatment after chemotherapy for people with high-risk peripheral T-cell lymphoma. It may help prevent the lymphoma from coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06538376Recruiting
New portable chest X-ray for ICU patients
This study tests a new portable chest X-ray that can be used in the ICU to check for problems like fluid in the lungs, trouble breathing, or swallowing issues. It is designed to help doctors see these problems more easily without moving you to the radiology department.
Boston, MassachusettsAges 18 years+ - NCT06543381RecruitingPhase 1
Olutasidenib for IDH1-mutated blood cancers after transplant
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
Duarte, CaliforniaAges 18 years+ - NCT06544863Recruiting
Better support for cirrhosis and liver transplant patients
This study tests a new care support program for people with cirrhosis or who have had a liver transplant. It aims to improve how patients are followed and helped at the hospital.
ParisAges 18 years+ - NCT06552169RecruitingPhase 2
Treg cell therapy to lower anti-rejection meds after kidney transplant
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
Phoenix, ArizonaAges 18–65 - NCT06554197Recruiting
CMV and EBV immune testing in half-matched stem cell transplant
This trial is for patients with blood disorders who are getting a half-matched stem cell transplant (from a family donor). It tests a new way to measure your immune system's response to two common viruses (CMV and EBV) after transplant, which may help doctors prevent or treat infections better.
Suzhou, JiangsuAges 16–60 - NCT06556485Recruiting
Early ablation for heart failure patients with heart pumps or on transplant list
This trial tests whether doing a catheter ablation early (before dangerous heart rhythms start) can help people with severe heart failure who need a heart transplant or already have an ICD. The goal is to see if this can improve outcomes.
Bad OeynhausenAges 18–99 - NCT06560801RecruitingPhase 4
Dapagliflozin for kidney health after transplant
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
Erlangen, BavariaAges 18–75 - NCT06567197Recruiting
MS treatment with stem cell transplant in the Netherlands
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
AmsterdamAges 18–65 - NCT06571825RecruitingPhase 4
Comparing transplant vs. venetoclax for older adults with AML
This trial tests whether a reduced-intensity stem cell transplant or venetoclax-based pills work better for patients aged 60-75 with high-risk acute myeloid leukemia who are already in remission.
Hangzhou, ZhejiangAges 60–75 - NCT06572462RecruitingPhase 2
Individual ATG dosing for stem cell transplant from unrelated donors
This trial tests a personalized dosing method for a medicine called ATG, which helps prevent your body from rejecting a donor stem cell transplant. It is for people with blood cancers who need a transplant from an unrelated donor.
BeijingAges 14–65
Hear when a new Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for transplant?
- Yes. Clin2 currently lists 1,499 recruiting transplant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a transplant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a transplant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.